235 related articles for article (PubMed ID: 35618884)
1. Brain-penetrant calcium channel blockers are associated with a reduced incidence of neuropsychiatric disorders.
Colbourne L; Harrison PJ
Mol Psychiatry; 2022 Sep; 27(9):3904-3912. PubMed ID: 35618884
[TBL] [Abstract][Full Text] [Related]
2. Onset and recurrence of psychiatric disorders associated with anti-hypertensive drug classes.
Colbourne L; Luciano S; Harrison PJ
Transl Psychiatry; 2021 May; 11(1):319. PubMed ID: 34039956
[TBL] [Abstract][Full Text] [Related]
3. Comparison of amlodipine versus other calcium channel blockers on blood pressure variability in hypertensive patients in China: a retrospective propensity score-matched analysis.
Zhang L; Yang J; Li L; Liu D; Xie X; Dong P; Lin Y
J Comp Eff Res; 2018 Jul; 7(7):651-660. PubMed ID: 29888950
[TBL] [Abstract][Full Text] [Related]
4. Calcium channel blockers for primary and secondary Raynaud's phenomenon.
Rirash F; Tingey PC; Harding SE; Maxwell LJ; Tanjong Ghogomu E; Wells GA; Tugwell P; Pope J
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD000467. PubMed ID: 29237099
[TBL] [Abstract][Full Text] [Related]
5. Calcium channel blockers for people with chronic kidney disease requiring dialysis.
Mugendi GA; Mutua FM; Natale P; Esterhuizen TM; Strippoli GF
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD011064. PubMed ID: 33000470
[TBL] [Abstract][Full Text] [Related]
6. Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients.
Taquet M; Sillett R; Zhu L; Mendel J; Camplisson I; Dercon Q; Harrison PJ
Lancet Psychiatry; 2022 Oct; 9(10):815-827. PubMed ID: 35987197
[TBL] [Abstract][Full Text] [Related]
7. Calcium channel blockers, survival and ischaemic stroke in patients with dementia: a Swedish registry study.
Kalar I; Xu H; Secnik J; Schwertner E; Kramberger MG; Winblad B; von Euler M; Eriksdotter M; Garcia-Ptacek S
J Intern Med; 2021 Apr; 289(4):508-522. PubMed ID: 32854138
[TBL] [Abstract][Full Text] [Related]
8. Calcium channel blockers for inhibiting preterm labour and birth.
Flenady V; Wojcieszek AM; Papatsonis DN; Stock OM; Murray L; Jardine LA; Carbonne B
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD002255. PubMed ID: 24901312
[TBL] [Abstract][Full Text] [Related]
9. Comparison between L-type and N/L-type calcium channel blockers in the regulation of home blood-pressure variability in elderly hypertensive patients.
Nozato S; Yamamoto K; Nozato Y; Takeda M; Hongyo K; Takeya M; Akasaka H; Takami Y; Takeya Y; Sugimoto K; Ito N; Rakugi H
Hypertens Res; 2018 Apr; 41(4):290-298. PubMed ID: 29449705
[TBL] [Abstract][Full Text] [Related]
10. Comparative Effectiveness of Renin-Angiotensin System Inhibitors and Calcium Channel Blockers in Individuals With Advanced CKD: A Nationwide Observational Cohort Study.
Fu EL; Clase CM; Evans M; Lindholm B; Rotmans JI; Dekker FW; van Diepen M; Carrero JJ
Am J Kidney Dis; 2021 May; 77(5):719-729.e1. PubMed ID: 33246024
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of fixed-dose combination therapy in the treatment of patients with hypertension: focus on amlodipine/valsartan.
da Silva PM
Clin Drug Investig; 2010; 30(9):625-41. PubMed ID: 20626210
[TBL] [Abstract][Full Text] [Related]
12. Magnitude of and Characteristics Associated With the Treatment of Calcium Channel Blocker-Induced Lower-Extremity Edema With Loop Diuretics.
Vouri SM; Jiang X; Manini TM; Solberg LM; Pepine C; Malone DC; Winterstein AG
JAMA Netw Open; 2019 Dec; 2(12):e1918425. PubMed ID: 31880802
[TBL] [Abstract][Full Text] [Related]
13. Incidence of neurodegenerative and cerebrovascular diseases associated with antihypertensive drug classes.
Harrison PJ; Colbourne L; Luciano S
Br J Psychiatry; 2021 May; 218(5):283-285. PubMed ID: 33407979
[TBL] [Abstract][Full Text] [Related]
14. Amlodipine treatment of hypertension associates with a decreased dementia risk.
Feldman L; Vinker S; Efrati S; Beberashvili I; Gorelik O; Wasser W; Shani M
Clin Exp Hypertens; 2016; 38(6):545-9. PubMed ID: 27392121
[TBL] [Abstract][Full Text] [Related]
15. The role of existing and newer calcium channel blockers in the treatment of hypertension.
Basile J
J Clin Hypertens (Greenwich); 2004 Nov; 6(11):621-29; quiz 630-1. PubMed ID: 15538095
[TBL] [Abstract][Full Text] [Related]
16. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records.
Taquet M; Geddes JR; Husain M; Luciano S; Harrison PJ
Lancet Psychiatry; 2021 May; 8(5):416-427. PubMed ID: 33836148
[TBL] [Abstract][Full Text] [Related]
17. A 10-year follow-up study of the association between calcium channel blocker use and the risk of dementia in elderly hypertensive patients.
Wu CL; Wen SH
Medicine (Baltimore); 2016 Aug; 95(32):e4593. PubMed ID: 27512890
[TBL] [Abstract][Full Text] [Related]
18. Dual calcium-channel blocker therapy in the treatment of hypertension.
Saseen JJ; Carter BL
Ann Pharmacother; 1996; 30(7-8):802-10. PubMed ID: 8826565
[TBL] [Abstract][Full Text] [Related]
19. S-amlodipine plus chlorthalidone vs. S-amlodipine plus telmisartan in hypertensive patients unresponsive to amlodipine monotherapy: study protocol for a randomized controlled trial.
Jo SH; Park SJ; Kim EJ; Kim SJ; Cho HJ; Song JM; Shin J; Park JJ; Shin JH; Han KR; Choi DJ
Trials; 2018 Jun; 19(1):324. PubMed ID: 29925421
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
